These findings suggest CCR5+ pro-NETotic neutrophils may act as a significant upstream driver of systemic immune activation and mucosal injury in IBD, representing a potential therapeutic target via CCR5+ antagonism or PAD4 inhibition.96 This evidence concerns the gene CCR5 and inflammatory bowel disease.